<DOC>
	<DOCNO>NCT01355523</DOCNO>
	<brief_summary>The purpose study investigate effect 6 mg melatonin daily 1 week preoperatively 12 week postoperatively depressive symptom , anxiety , cognitive function sleep disturbance breast cancer patient . Furthermore investigator examine whether specific clock-gene ( HPER3 ) correlate increase risk depression , sleep disturbance cognitive dysfunction .</brief_summary>
	<brief_title>The Effect Melatonin Depression , Anxiety , Cognitive Function Sleep Disturbances Breast Cancer Patients</brief_title>
	<detailed_description>About 1.4 million woman diagnose breast cancer every year . Breast cancer common malignancy among woman worldwide constitute 1/5 cancer type . Breast cancer diagnosis treatment , month follow primary therapy stressful time woman . Aside actual `` cancer threat '' many woman experience various degree depression , anxiety , sleep disturbance memory/concentration problem ( cognitive dysfunction ) . Naturally factor influence quality life also contribute morbidity mortality . Melatonin regulatory circadian hormone , among others , hypnotic , sedative , anxiolytic possibly anti-depressive effect . It low toxicity adverse effect . The purpose project test melatonin ( 6 mg daily 1 week preoperatively 12 week postoperatively ) breast cancer patient hopefully hereby able prevent depression , anxiety , sleep disturbance cognitive dysfunction . On overall perspective hopefully contribute improve quality life patient extend lifetime . Furthermore investigator examine whether specific gene call clock-gene ( HPER3 ) correlate increase risk depression , sleep disturbance cognitive dysfunction . If case could become possible identify woman increase risk provide prophylactic treatment risk develop depression , sleep disturbance cognitive disturbance . Sample size calculation base primary outcome parameter . Using conservative estimate incidence depression , investigator expect find reduction 30 % 15 % melatonin treatment . Sample size sufficient include secondary tertiary outcome parameter well . The sample size calculation calculate power 80 % , type I error 5 % type II error 20 % .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Dyssomnias</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>Women , age 3075 , breast cancer admit lumpectomy mastectomy Herlev Hospital ASA score IIII No sign depression measure Major Depression Inventory ( MDI ) Not pregnant Neoadjuvant chemotherapy Treatment SSRI , Warfarin anticoagulant ( except 75 mg ASA daily ) , MAO inhibitor calcium blocker Rotor DubinJohnson syndrome Epilepsy Known allergic reaction melatonin Known treat sleep apnea Diabetes Mellitus insulin treat Ongoing previous medically treat depression bipolar disorder Known autoimmune disease systemic lupus erythematosus ( SLE ) , rheumatoid arthritis ( RA ) , sclerose Incompensated liver cirrhosis Severe kidney disease Previous current cancer Known medically treat sleepdisorder ( insomnia , restless leg etc ) Shiftwork nightwork Daily alcohol intake 5 unit Preoperative treatment psychopharmacological drug , opioids anxiolytic ( include sleep pill ) Predicted bad compliance Pregnant breastfeed Preoperative Mini Mental State Evaluation ( MMSE ) score less 24</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Breast cancer surgery</keyword>
	<keyword>Melatonin</keyword>
	<keyword>Depression</keyword>
	<keyword>Anxiety</keyword>
	<keyword>Sleep disturbance</keyword>
	<keyword>Cognitive function</keyword>
</DOC>